Dec 6, 2017 Cellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort in Phase 2 Trial of CLR 131 Learn More
Nov 9, 2017 Cellectar Biosciences Reports Third Quarter 2017 Financial and Corporate Performance Learn More
Nov 7, 2017 Cellectar Announces Updated Median Overall Survival of 26.2 Months from Cohort 1 of CLR 131 Phase 1 Trial in Advanced Multiple Myeloma Learn More